Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of dabrafenib + trametinib in pediatric BRAF V600-mutant low-grade or relapsed/refractory high-grade glioma
NL-OMON50503Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Apr 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dabrafenib + trametinib, trametinib, carboplatin and vincristine in glioma (3 arms), sponsored by Novartis. Primary endpoint: Overall response rate. Started Apr 2019; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinibcarboplatinvincristine
03
Conditions
glioma
Beyond the preview
Go deeper on NL-OMON50503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50503.